These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 22146025)
1. What's wrong with chemoprevention of prostate cancer? Justman S Am J Bioeth; 2011 Dec; 11(12):21-5. PubMed ID: 22146025 [TBL] [Abstract][Full Text] [Related]
2. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. Musquera M; Fleshner NE; Finelli A; Zlotta AR Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological approaches to reducing the risk of prostate cancer. Rittmaster RS; Fleshner NE; Thompson IM Eur Urol; 2009 May; 55(5):1064-73. PubMed ID: 19200641 [TBL] [Abstract][Full Text] [Related]
4. Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity. Helfand BT; Blackwell RH; McVary KT J Urol; 2010 Jul; 184(1):218-23. PubMed ID: 20483154 [TBL] [Abstract][Full Text] [Related]
5. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586 [TBL] [Abstract][Full Text] [Related]
6. [Dutasteride provides chemoprevention]. Werner F Aktuelle Urol; 2006 Sep; 37(5 Suppl):18. PubMed ID: 23646395 [No Abstract] [Full Text] [Related]
7. Ask the doctor. I take Avodart for my enlarged prostate. But I heard that Avodart increases prostate cancer risk. Is that true? Should I quit taking Avodart? Garnick MB Harv Health Lett; 2012 Jan; 37(3):8. PubMed ID: 22400165 [No Abstract] [Full Text] [Related]
8. The effect of short-term dutasteride intake in early-stage prostate cancer: analysis of 148 patients who underwent three-dimensional prostate mapping biopsy. Barqawi AB; O'Donnell CI; Siomos VJ; Hou AH Urology; 2010 Nov; 76(5):1067-71. PubMed ID: 20472268 [TBL] [Abstract][Full Text] [Related]
9. Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen. Svatek RS; Lotan Y Cancer Prev Res (Phila); 2011 Feb; 4(2):277-83. PubMed ID: 21163937 [TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of prostate cancer. Walsh PC N Engl J Med; 2010 Apr; 362(13):1237-8. PubMed ID: 20357287 [No Abstract] [Full Text] [Related]
11. [Practical follow-up of a patient treated with finasteride in screening for prostate cancer]. Villers A Prog Urol; 2008 Apr; 18 Suppl 3():S58-62. PubMed ID: 18455086 [TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial. Kattan MW; Earnshaw SR; McDade CL; Black LK; Andriole GL Appl Health Econ Health Policy; 2011 Sep; 9(5):305-15. PubMed ID: 21875161 [TBL] [Abstract][Full Text] [Related]
13. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. Andriole GL; Marberger M; Roehrborn CG J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723 [TBL] [Abstract][Full Text] [Related]
14. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979 [TBL] [Abstract][Full Text] [Related]
15. 5-α reductase inhibitors and prostate cancer prevention: where do we turn now? Hamilton RJ; Freedland SJ BMC Med; 2011 Sep; 9():105. PubMed ID: 21920036 [TBL] [Abstract][Full Text] [Related]
16. The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. Theoret MR; Ning YM; Zhang JJ; Justice R; Keegan P; Pazdur R N Engl J Med; 2011 Jul; 365(2):97-9. PubMed ID: 21675880 [No Abstract] [Full Text] [Related]
17. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. Sartor O; Gomella LG; Gagnier P; Melich K; Dann R Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455 [TBL] [Abstract][Full Text] [Related]
18. [Chemoprevention of prostate cancer - a plea]. Schmitz-Dräger BJ; Bismarck E; Schöffski O; Fischer C Aktuelle Urol; 2012 May; 43(3):157-61. PubMed ID: 22639024 [TBL] [Abstract][Full Text] [Related]
19. Update on prostate cancer chemoprevention. Lowe JF; Frazee LA Pharmacotherapy; 2006 Mar; 26(3):353-9. PubMed ID: 16503715 [TBL] [Abstract][Full Text] [Related]
20. Study supports PSA velocity risk count. Fillon M J Natl Cancer Inst; 2012 Jul; 104(14):1042-3. PubMed ID: 22781432 [No Abstract] [Full Text] [Related] [Next] [New Search]